| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/29/2003 | EP1278774A2 Human g-protein coupled receptors |
| 01/29/2003 | EP1278772A2 Glucagon antagonists |
| 01/29/2003 | EP1278771A2 A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof |
| 01/29/2003 | EP1278770A1 Human wingless-like gene |
| 01/29/2003 | EP1278769A2 Tuberculosis antigens and methods of use thereof |
| 01/29/2003 | EP1278767A1 Albumin fusion proteins |
| 01/29/2003 | EP1278765A2 Immunodominant acetylcholine receptor alpha subunit peptides, complexes thereof with mhc class ii components and their use |
| 01/29/2003 | EP1278761A2 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
| 01/29/2003 | EP1278574A2 Topical composition for the treatment of psoriasis and related skin disorders |
| 01/29/2003 | EP1278551A2 Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
| 01/29/2003 | EP1278549A2 Cyclodextrin containing glycopeptide antibiotic compositions |
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP1278542A2 Molecular antigen arrays and vaccines |
| 01/29/2003 | EP1278540A2 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 01/29/2003 | EP1278537A2 Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis |
| 01/29/2003 | EP1278536A1 Depletion method of blood plasma ascorbate |
| 01/29/2003 | EP1278535A2 Uses of tgap7 for the modulation of leucocyte activation |
| 01/29/2003 | EP1278534A1 Methods and compositions for impairing multiplication of hiv-1 |
| 01/29/2003 | EP1278530A2 Chemical modification of mammalian urine and blood |
| 01/29/2003 | EP1278525A2 Methods and compositions for enhancing cellular function through protection of tissue components |
| 01/29/2003 | EP1278523A2 Combination of progesterone and mifepristone for cancer therapy |
| 01/29/2003 | EP1278516A1 Powders for use in a dry powder inhaler |
| 01/29/2003 | EP1265570A4 Soluble keratin peptide |
| 01/29/2003 | EP1137465A4 Method for purification of a blood component |
| 01/29/2003 | EP0961824A4 Method of activating dendritic cells |
| 01/29/2003 | EP0862451B1 Composition for improving pancreatic function |
| 01/29/2003 | EP0858465B1 Anti-tumoral protein |
| 01/29/2003 | EP0831868B1 Monitoring efectiveness of topically applied androgens in sjögren's syndrome by dtetecting tgf-beta in tears |
| 01/29/2003 | EP0754192B1 Circularly permuted ligands and circularly permuted chimeric molecules |
| 01/29/2003 | EP0753005B1 Cytotoxic t-cell lymphocyte ("ctl") activity regulation by class i mhc peptides |
| 01/29/2003 | EP0703980B1 Intracellular binding proteins and use thereof |
| 01/29/2003 | EP0546007B2 Product and use of it for the treatment of catabolic states comprising authentic igf-1 and hypocaloric amount of nutritients |
| 01/29/2003 | CN1394199A Peptide derivatives and their pharmaceutically acceptable salts, processes for preparation of both, and use thereof |
| 01/29/2003 | CN1393557A Polypeptide-human protein-14.08 containing peptidyl-prolyl cis-trans isomerase characteristic sequence fragment and polynucleotide for coding it |
| 01/29/2003 | CN1393555A Polypeptide-proteasome-61.82 and polynucleotide for coding it |
| 01/29/2003 | CN1393554A Polypeptide-human protein-9.57 containing glycosylhydrolase family 17 characteristic sequence fragment and polynucleotide for coding it |
| 01/29/2003 | CN1393553A Polypeptide-human phosphatidase-30.47 and polynucleotide for coding it |
| 01/29/2003 | CN1393552A Polypeptide-human myotonic dystrophy protein kinase -61.27 and polynucleotide for coding it |
| 01/29/2003 | CN1393550A Polypeptide-human respiratory chain CoQ oxide-reductase-11.22 and polynucleotide for coding it |
| 01/29/2003 | CN1393548A Polypeptide-human protein-13.2 containing site specific recombinase characteristic sequence fragrant and polynucleotide for coding it |
| 01/29/2003 | CN1393452A Memory clearing protein and its application |
| 01/29/2003 | CN1393266A Slow-releasing hirudin medicine applied orally |
| 01/29/2003 | CN1393265A Method for reducing fasting blood-glucose of diabetic and weight |
| 01/29/2003 | CN1393264A Application of herberine as sensibilizer of insulin |
| 01/29/2003 | CN1393263A Health-care food for improving prostatoplasia |
| 01/29/2003 | CN1393218A Biodegradable durable medicine releasing system |
| 01/29/2003 | CN1393217A Release system for hydrophilic medicines containing polyether |
| 01/29/2003 | CN1100142C Process for preparing natto kinase and its application |
| 01/29/2003 | CN1099893C Sustained-release preparation |
| 01/28/2003 | USRE37971 Selective acylation of epsilon-amino groups |
| 01/28/2003 | US6512166 Combinations of fungal cell wall degrading enzyme and fungal cell membrane affecting compound |
| 01/28/2003 | US6512104 Interleukin-1β converting enzyme like cysteine protease |
| 01/28/2003 | US6512103 Mammalian chemokine reagents |
| 01/28/2003 | US6512102 Compositions and methods of diagnosis and treatment using casein kinase I |
| 01/28/2003 | US6512097 Chimeric molecules that specifically bind a tumor cell bearing a c-erbB-2; immunotherapy |
| 01/28/2003 | US6512095 Nucleotide sequeces coding protein for use in the detetion, diagnosis and treatment cell proliferative, autoimmune diseases and infection |
| 01/28/2003 | US6512093 said fatty acids being chlorinated fatty acids of the olive oil. |
| 01/28/2003 | US6512092 Solid phase peptide synthesis; in situ generation of amino acid chloride by deblocking; coupling sterically hindered amino acid residues |
| 01/28/2003 | US6512001 D-proline derivatives |
| 01/28/2003 | US6511979 Methods for treating conditions modulated by lactosylceramide |
| 01/28/2003 | US6511968 COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of aspirin; does not contain HMG-CoAreductase inhibitor |
| 01/28/2003 | US6511963 Treating excitotoxicity resulting from over- stimulation of the NMDA receptor which comprises administering agent selected from the group consisting of Conantokin-G, a Conantokin-G derivative and salts thereof |
| 01/28/2003 | US6511962 Intermediates useful for synthesizing laspartomycin derivatives as well as the laspartomycin derivatives |
| 01/28/2003 | US6511961 Treating allergic inflammatory disease or hepatitis comprising administering to a subject an effective amount of a cyclic peptide having VLA-4 (very late antigen-4) adhesion activity |
| 01/28/2003 | US6511959 Cytotoxic treatment of tumors selected from the group consisting of carcinomas, melanomas and hematological malignancies, which comprises administering for CANP, thus inhibiting growth of the tumors |
| 01/28/2003 | US6511847 Recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect in the transfected cells; tumor suppressor gene |
| 01/28/2003 | US6511839 Promoter polynucleotides |
| 01/28/2003 | US6511830 Envelope protein gp 160 |
| 01/28/2003 | US6511827 Nucleotide encoding human galanin receptor 3 (GALR3) |
| 01/28/2003 | US6511826 For use in diagnosis therapy |
| 01/28/2003 | US6511825 Cell signaling polypeptides and nucleic acids |
| 01/28/2003 | US6511823 Novel DNA and amino acid sequences; expression vectors and host cells useful in a method for production of the HBNF protein |
| 01/28/2003 | US6511811 Protein kinase C antagonist related to insulin receptor |
| 01/28/2003 | US6511807 Carbohydrate ligand that specifically binds to a leczyme; nucleic acid sequence encoding a nonclassical MHC class I heavy chain; ability to associate with a beta 2 microglobulin; major histocompatibility complex transplantation molecules |
| 01/28/2003 | US6511666 Purified antigenic complex comproised of multimeric protein complexes of arginine- and lysine-specific thiol endopepti-dases containing adhesion domains; raising antibody response against porphyromonas gingivalis |
| 01/28/2003 | US6511664 Antiinflammatory |
| 01/28/2003 | US6511663 Tri- and tetra-valent monospecific antigen-binding proteins |
| 01/28/2003 | US6511662 Treatment of cytomegalovirus using aminopeptidase N |
| 01/28/2003 | US6511648 Vitronectin receptor antagonist pharmaceuticals |
| 01/28/2003 | CA2318432C The use of isolated domains of type iv collagen to modify cell and tissue interactions |
| 01/28/2003 | CA2284910C Pharmaceutical combined preparations containing erythropoietin and iron preparations |
| 01/28/2003 | CA2258906C Amides |
| 01/28/2003 | CA2222698C Use of bradykinin antagonists for stimulating or inducing hair growth and/or arresting hair loss |
| 01/28/2003 | CA2158425C Diagnostic and treatment of erectile dysfunction |
| 01/28/2003 | CA2127553C Peptides with organo-protective activity, process for their preparation and their use in the therapy |
| 01/28/2003 | CA2124375C Compounds containing a fused bicyclic ring and processes therefor |
| 01/28/2003 | CA2110556C The elucidation and synthesis of antineoplastic tetrapeptide phenylamides of dolastatin 10 |
| 01/28/2003 | CA2110555C Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| 01/28/2003 | CA2072008C Immunologically active proteins from borrelia burgdorferi, related test kits which contain these proteins and are suitable for detecting antibodies in test fluids, and the use of these proteins as vaccines against infections caused by borrelia strains |
| 01/28/2003 | CA2033469C Composition and method for the treatment of osteoporosis in mammals |
| 01/27/2003 | CA2391642A1 Identification and use of molecules implicated in pain |
| 01/27/2003 | CA2391219A1 Identification and use of molecules implicated in pain |
| 01/27/2003 | CA2391216A1 Identification and use of molecules implicated in pain |
| 01/27/2003 | CA2391112A1 Identification and use of molecules implicated in pain |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006995A2 Method for identifying substances which modulate interleukin 4 (il-4) signaling |
| 01/23/2003 | WO2003006993A2 Gel compositions |
| 01/23/2003 | WO2003006893A2 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | WO2003006691A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 01/23/2003 | WO2003006689A2 Diagnosis and treatment of diseases associated with altered expression of hipk1 |